Evident, Corista, Sakura Finetek USA and Visiopharm team up to drive quality and efficiency in pathology

WALTHAM, Mass., (Sept. 19, 2023)—Evident announced an alliance with Corista, Sakura Finetek USA and Visiopharm to deliver an automated, end-to-end workflow solution for pathology in the USA. Together, the scientific leaders will combine their technologies to streamline the workflow of staining, imaging, and analyzing whole slide images with the collaboration and management needed in today’s high-volume laboratories.

Demand for efficient pathology and quality control of sample handling has increased in recent years. The collaboration of these technology leaders supports customers in their transition to a digital workflow by combining histopathology, digital pathology, and computational pathology.

Evident and Corista, leaders in image management solutions, previously developed a high-end scanner with a modern image management system that leverages Visiopharm’s image analysis and artificial intelligence (AI) toolset. Sakura Finetek USA and Evident have also collaborated, delivering an automated staining and whole slide imaging workflow to reduce manual tasks across pathology labs in clinical and life science organizations.

“The alliance of these four companies will help drive the adoption of a fully automated pathology system across laboratories,” said Lee Wagstaff, the Vice President of Life Science Sales and Marketing at Evident Americas. “We look forward to supporting our mutual customers with a complete end-to-end digital pathology solution to drive efficiency and reduce manual tasks as pathology testing volume ramps up.”

“Supporting pathology laboratories in driving better patient outcomes that are sustainable and effective is at the heart of what we do,” said Corista CEO Elizabeth Wingard. “This alliance will help our customers with better collaboration across their consulting and analysis workflows.” 

“Working together will help move computational pathology to the forefront through a scalable and integrated system,” said Visiopharm CEO Michael Grunkin. “Our AI-driven precision pathology software integrated with our partners’ technology yields more effective, robust performance that reduces manual workflows and time-consuming tasks.”

“We are excited to offer customers the ability to enhance patient care with an end-to-end automated workflow,” added Patrick Devor, the Vice President of Sales at Sakura Finetek USA, Inc. “This alliance will enable us to increase the level of automation across histopathology, drive quality, and reduce turnaround time, which has been a goal of Sakura Finetek since 1870.”

About Evident

At Evident, we are guided by the scientific spirit—innovation and exploration are at the heart of what we do. Committed to making people’s lives healthier, safer and more fulfilling, we support our customers with solutions that solve their challenges and advance their work; whether it’s researching medical breakthroughs, inspecting infrastructure, or exposing hidden toxins in consumer products.

Evident Life Science empowers scientists and researchers through collaboration and cutting-edge life science solutions. Dedicated to meeting the challenges and supporting the evolving needs of its customers, Evident Life Science advances a comprehensive range of microscopes for pathology, hematology, IVF and other clinical applications as well as for research and education.

For more information, visit EvidentScientific.com.

About Corista

Corista delivers the industry’s most extensive array of workflow, analytical and collaborative tools for pathology. Medical centers can seamlessly integrate with LIS/EHRs in a unified digital environment of whole slide, gross and static pathology images. Physicians have 21st century tools to collaborate, communicate, teach, and report with access to ‘best of breed’ image analytics. Specialists can receive digital consults from remote physicians and patients from across the globe, and investigator-initiated researchers have a research and development platform to develop and apply their algorithms. Corista provides a new level of interoperability for pathology, integrating whole slide image scanning systems, image analytics, and LIS/EHR platforms with a rich, collaborative environment for physicians, patients, biotech, and pharmaceutical scientists. This is Integrated Pathology^™ only from Corista.

About Sakura Finetek USA

With the U.S. office based in Torrance, California, Sakura Finetek is the global leader in continuous innovation for pathology by providing integrated solutions for anatomic pathology and patients through best-in-class innovation, quality and customer care. With a strategic focus on end-to-end automation, Sakura Finetek continues to lead the industry in the development and commercialization of automated histology instrumentation and consumables for anatomic pathology.

Sakura Finetek solutions dramatically increase efficiency, standardize results, and enable pathology laboratories to manage their daily workload more simply while significantly impacting patient care.

For more information, visit Sakuraus.com.

About Visiopharm

Visiopharm® is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no less than eight diagnostic algorithms cleared under IVDR for EU customers. These applications provide diagnostic decision support and and can be easily activated and integrated into existing lab workflows.

Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with offices in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.

Contact: 

Johanne Louise Brændgaard
Chief Marketing Officer
jlb@visiopharm.com